Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human PPSGG (PN-1007) study in anti-MAG neuropathy
NL-OMON49059Phase 1Completed
- Sponsor
- Polyneuron Pharmaceuticals AG
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PN-1007 in anti-myelin-associated glycoprotein neuropathy (7 cohorts), sponsored by Polyneuron Pharmaceuticals AG. Started Nov 2020; status: completed.
02
Drugs
PN-1007
03
Conditions
anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on NL-OMON49059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49059.